US Patent Issued to NUVOBIO on March 31 for "Peptide-derived therapeutics targeting KDM5C for the treatment of cancer" (Canadian Inventors)

ALEXANDRIA, Va., March 31 -- United States Patent no. 12,589,160, issued on March 31, was assigned to NUVOBIO Corp. (Canada).

"Peptide-derived therapeutics targeting KDM5C for the treatment of cancer" was invented by Kyle Kevin Biggar (Nepean, Canada), Hemanta Adhikary (Nepean, Canada) and Matthew Jacob Hoekstra (Georgetown, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to treatment of cancer. In particular, the present invention relates to peptides that bind KDM5C for the treatment of cancer."

The patent was filed on March 12, 2020, under Application No. 17/438,925.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/net...